Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

25 de septiembre de 2026 actualizado por: CHAO-HUNG WANG, MD, Chang Gung Memorial Hospital

Integration of Metabolic Assessment on Phenylalanine Axis and Clinical Databank-based Artificial Intelligence Computation in Heart Failure: Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

Heart failure is a complex clinical syndrome with high hospitalization rates and high mortality risks. While N-terminal-pro B-type natriuretic peptide (NT-proBNP) is widely used in clinical practice to assist in diagnosis and assessment, its ability to detect prognosis in heart failure remains insufficient. Recent scientific research has found that phenylalanine in the blood and its endogenous toxic substance phenylpyruvate are closely related to impaired energy synthesis in heart muscle cells, making them highly promising next-generation long-term biomarkers. Our research team has previously developed a "risk score" prediction model that combines phenylpyruvate levels in the blood with clinical data; this project aims to further confirm its clinical value.

Therefore, the investigators cordially invite heart failure patients who are being followed up in the cardiology outpatient clinic to have their "phenylalanine" and "phenylpyruvic acid" concentrations measured in a small amount of blood. This data, combined with clinical data, will be used to calculate a "Risk Score" to identify high-risk heart failure patients earlier.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

I. Background:

Heart failure is a complex syndrome. Any abnormality in cardiac structure or function that affects ventricular congestion or ejection can lead to heart failure. Clinically, heart failure is classified into four categories based on the presence or absence of abnormal left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with normal left ventricular ejection fraction (LVEF ≥ 50%), and heart failure with improved ejection fraction (HFimpEF) (previously LVEF ≤ 40%, followed by follow-up to LVEF > 40%). The New York Heart Association functional classification (NYHA Fc) further classifies participants into grades I through IV based on the degree of limitation in physical activity. Participants diagnosed with HFrEF who exhibit symptoms of NYHA Fc grades 2 to 4 require guideline-directed medical therapy (GDMT). However, a good assessment strategy for long-term follow-up after treatment remains lacking.

Among existing diagnostic and treatment strategies, NT-proBNP is the most widely used biomarker for diagnosis and prognostic assessment. However, its ability to identify early abnormalities of heart failure relapse, quantify metabolic abnormalities caused by heart failure, and detect endogenous toxicities caused by heart failure is still insufficient, and its assessment of heart failure prognosis is also imprecise. Elevated blood concentrations of phenylalanine and its metabolite phenylpyruvate are currently considered highly relevant to the pathophysiological mechanisms of heart failure exacerbation and can lead to the accumulation of phenylalanine and its downstream metabolite phenylpyruvate in the body fluids and tissues of heart failure patients, further worsening cardiac function. Furthermore, these metabolic disorders are closely associated with oxidative stress, mitochondrial dysfunction, and impaired energy synthesis. These alterations have been confirmed in animal models and clinical patients. They hold great potential as biomarkers for long-term monitoring by capturing early metabolic abnormalities and endogenous toxicities in heart failure.

Therefore, this study focuses on phenylalanine and phenylpyruvate metabolites to assess their correlation with patient prognosis. In another part, the investigators used the Chang Gung database for data analysis and integrated metabolite testing and clinical data into a "Risk Score" to identify high-risk patients. This aims to provide heart failure patients with more precise metabolic assessment and clinical management tools, thereby improving their quality of life and reducing disease-related mortality and hospitalization rates.

II. Objectives:

  1. To uniformly quantify phenylalanine and phenylpyruvate using high-order mass spectrometry and verify their correlation with the worsening of heart failure.
  2. To use the developed "Risk Score" in prospective, multicenter, observational validation studies (including Chang Gung Memorial Hospital, Mackay Memorial Hospital, Cheng Hsin General Hospital, and National Taiwan University Hospital) to assess its clinical predictive ability, calibration, discrimination, and cross-center generalization ability in participants with chronic outpatient heart failure.

III. Methods The investigators will enroll participants at outpatient clinic at different hospitals. Then, fasting blood (3 ml) will be collected once to get the plasma after centrifugation. Phenylpyruvate (PPA) concentration will be measured by liquid chromatography-mass spectrometry (LC-MS/MS).

Based on clinical information and the blood levels of NT-proBNP and PPA, a risk score will be calculated.

For clinical outcomes, the investigators will follow up participants' events of recurrent worsening heart failure, which will be explained in the primary and secondary outcome section.

The investigators will do statistical analysis to see the prognostic value of PPA concentrations and the risk scores.

Tipo de estudio

De observación

Inscripción (Estimado)

800

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Chao-Hung Wang, MD, PhD
  • Número de teléfono: 0975360604
  • Correo electrónico: bearty54@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Outpatients with chronic heart failure

Descripción

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

Exclusion Criteria:

  • Patients with other serious comorbidities that significantly impact life expectancy or survival within three months based on clinical assessment, such as terminal cancer or severe multiple organ failure.
  • Patients with New York Heart Association (NYHA) class IV and unstable clinical condition requiring frequent intravenous therapy or hospitalization.
  • Patients currently receiving maintenance hemodialysis or peritoneal dialysis.
  • Patients who are unable to complete basic follow-up, lack key clinical data, or do not consent to the use of the specimen and data.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
outpatients with chronic heart failure

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Recurrent worsening heart failure (HF) event burden
Periodo de tiempo: within 36 months after enrollment

Recurrent worsening heart failure (HF) event burden within 36 months after enrollment. Events include:

  1. Hospitalization for worsening HF
  2. HF worsening treated at emergency or outpatient clinic
  3. intensive diuretic care event
  4. All-cause death
within 36 months after enrollment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Composite events
Periodo de tiempo: within 36 months after enrollment
  1. First hospitalization for worsening heart failure, emergency heart failure care, or all-cause death within 36 months
  2. Number of heart failure hospitalizations, number of emergency/unexpected care visits, and total days of hospitalization within 36 months
within 36 months after enrollment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

18 de septiembre de 2026

Finalización primaria (Estimado)

31 de octubre de 2030

Finalización del estudio (Estimado)

31 de octubre de 2030

Fechas de registro del estudio

Enviado por primera vez

18 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Publicado por primera vez (Actual)

24 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 202500252B0C6002

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir